Indeed, sequential or combinatorial blockade of TIM‐3 and PD‐1/PD‐L1 has shown enhanced antitumor efficacy in several murine models172, 180, 183, 184 and dual blockade of these checkpoints augments the effector activity of ex vivo‐stimulated CD8+ TIL from hepatocellular carcinoma patients.185. The gene discussed is CD8A; the disease is hepatocellular carcinoma.